Preface

Preface Publisher

Keshavarzfathi M^{1, 2, 3} ; Rezaei N^{3, 4, 5}

Show Affiliations

1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
3. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives Published:2018

[No abstract available]

Style	Citing Format
MLA	Keshavarzfathi M, Rezaei N. "Preface." Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, vol. , no. , 2018, pp. xiii-.
APA	Keshavarzfathi M, Rezaei N (2018). Preface. Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, (), xiii-.
Chicago	Keshavarzfathi M, Rezaei N. "Preface." Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives , no. (2018): xiii-.
Harvard	Keshavarzfathi M, Rezaei N (2018) 'Preface', Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, (), pp. xiii-.
Vancouver	Keshavarzfathi M, Rezaei N. Preface. Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives. 2018;():xiii-.
BibTex	@article{ author = {Keshavarzfathi M and Rezaei N}, title = {Preface}, journal = {Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives}, volume = {}, number = {}, pages = {xiii-}, year = {2018} }
RIS	TY - JOUR AU - Keshavarzfathi M AU - Rezaei N TI - Preface JO - Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives VL - IS - SP - xiii EP - PY - 2018 ER -